Compare COOK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | MNOV |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.7M | 72.7M |
| IPO Year | 2021 | 2004 |
| Metric | COOK | MNOV |
|---|---|---|
| Price | $28.17 | $1.49 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $58.00 | $8.00 |
| AVG Volume (30 Days) | ★ 535.0K | 60.3K |
| Earning Date | 03-05-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $0.48 | $1.13 |
| 52 Week High | $35.56 | $1.96 |
| Indicator | COOK | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 79.73 | 52.26 |
| Support Level | $0.98 | $1.23 |
| Resistance Level | N/A | $1.62 |
| Average True Range (ATR) | 1.45 | 0.07 |
| MACD | 3.40 | 0.01 |
| Stochastic Oscillator | 77.71 | 88.64 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.